Skip to content
value.today

Alpine Immune Sciences, Inc.

Total raised
$1 M
1 round on record
Latest round
$1 M
Jan 2015
First round on record
Jan 2015
Today
Went public
See the company page

Alpine Immune Sciences, Inc. is listed today as Alpine Immune Sciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Alpine Immune Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2017$17 MPrivate placement after listing$10 to $50 million

Alpine Immune Sciences, Inc.: Private sale, Jul 2017

Investors in this round

3 investors had bought by the notice of Jul 24, 2017: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • J. Paul H. Rickey · Executive Officer
  • Jay H. Venkatesan · Executive Officer, Director
  • Mitchell H. Gold · Executive Officer, Director
  • Stanford H. Pang · Executive Officer
  • James H. Topper · Director
  • Peter H. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “The proposed merger between Alpine Immune Sciences, Inc. and Nautilus Merger Sub, Inc. (a wholly owned subsidiary of Nivalis Therapeutics, Inc.) is conditioned upon, among other things, the closing of this offering.”

Signed by J. Paul Rickey, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 24, 2017. Read the notice at the SEC.

equitySEC
Jun 2016$10 MPrivate placement after listing$10 to $50 million

Alpine Immune Sciences, Inc.: Private sale, Jun 2016

Investors in this round

3 investors had bought by the notice of Jun 21, 2016: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $48 M offered; $38 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David H. Miller · Executive Officer
  • Jay Venkatesan · Executive Officer, Director
  • Michael H. Kornacker · Executive Officer
  • Mitchell H. Gold · Executive Officer, Director
  • Ryan H. Swanson · Executive Officer
  • James H. Topper · Director
  • Peter H. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Miller, Secretary. Source: SEC Form D, newest notice filed Jun 21, 2016. Read the notice at the SEC.

equitySEC
Jan 2015$1 MNo. 1Under $2 million

Alpine Immune Sciences, Inc.: Raise no. 1, Jan 2015

Investors in this round

1 investor had bought by the notice of May 13, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Miller · Executive Officer, Director
  • Dr. Mitchell H Gold · Executive Officer, Director
  • Michael H Kornacker · Executive Officer, Director
  • Ryan H Swanson · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Miller, Secretary. Source: SEC Form D and 1 amendment, newest notice filed May 13, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Alpine Immune Sciences, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2017).

    SEC Form D · Jul 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2017

That is all the official record says: Alpine Immune Sciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Alpine Immune Sciences, Inc. are on record.

Investors#

No investor of Alpine Immune Sciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Alpine Immune Sciences, Inc.
NameRoleNamed in
J. Paul H. RickeyExecutive officerJul 2017
Jay H. VenkatesanExecutive officerJul 2017
Mitchell H. GoldExecutive officerJul 2017
Stanford H. PangExecutive officerJul 2017
David H. MillerExecutive officerJun 2016
Jay VenkatesanExecutive officerJun 2016
Michael H. KornackerExecutive officerJun 2016
Ryan H. SwansonExecutive officerJun 2016
David MillerExecutive officerMay 2015
Dr. Mitchell H GoldExecutive officerMay 2015
Michael H KornackerExecutive officerMay 2015
Ryan H SwansonExecutive officerMay 2015
James H. TopperDirectorJul 2017
Jay H. VenkatesanDirectorJul 2017
Mitchell H. GoldDirectorJul 2017
Peter H. ThompsonDirectorJul 2017
Jay VenkatesanDirectorJun 2016
David MillerDirectorMay 2015
Dr. Mitchell H GoldDirectorMay 2015
Michael H KornackerDirectorMay 2015
Ryan H SwansonDirectorMay 2015

About

Company in Seattle, United States.

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.